LAMIVUDINE and ZIDOVUDINE
LAMIVUDINE and ZIDOVUDINE is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: LAMIVUDINE and ZIDOVUDINE; Generic name: LAMIVUDINE AND ZIDOVUDINE; Drug class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC].
| Brand name | LAMIVUDINE and ZIDOVUDINE |
|---|---|
| Generic name | LAMIVUDINE AND ZIDOVUDINE |
| Drug class | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] |
| Manufacturer | Bryant Ranch Prepack |
| Used for | 1 INDICATIONS & USAGE Lamivudine and zidovudine tablets a combination of 2 nucleoside analogues, are indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Lamivudine and zidovudine tablets, a combination of 2 nucleoside analogue reverse transcriptase inibitors, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. (1) |
| Dosage | 2 DOSAGE & ADMINISTRATION • Adults and Adolescents weighing greater than or equal to 30 kg: 1 tablet orally twice daily. (2.1) • Pediatrics weighing greater than or equal to 30 kg: 1 tablet orally twice daily. (2.2) • Because lamivudine and zidovudine tablet is a fixed-dose tablet and cannot be dose adjusted, lamivudine and zidovudine tablet is not recommended in patients requiring dosage adjustment or with hepatic impairment or experiencing dose-limiting adverse reactions. (2.3, 4) 2.1 Recommen |
| Warnings | BOXED WARNING WARNING: HEMATOLOGIC TOXICITY, MYOPATHY, LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, and EXACERBATIONS OF HEPATITIS B Zidovudine, a component of lamivudine and zidovudine tablets, has been associated with hematologic toxicity including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus (HIV-1) disease [see Warnings and Precautions (5.1)]. Prolonged use of zidovudine has been associated with symptomatic myopathy [see Warnin |
| Active ingredient(s) | LAMIVUDINE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=005f1b9d-1950-4ef3-a9d6-c428a40a3630 |